When extrapolating from the metastatic melanoma literature, these observations, supporting neoadjuvant immunotherapy over targeted therapy, were further corroborated, in the DREAMseq trial, which investigated which initial treatment for BRAF-mutated melanoma was more effective [65]. This evidence concerns the gene BRAF and melanoma.